Human Peptides ACTH (1-39) Seractide 10mg/Vial for Adrenal insufficiency

Human Peptides ACTH (1-39) Seractide 10mg/Vial for Adrenal insufficiency

Product Name:Seractide
CAS:12279-41-3
MF:C207H308N56O58S1
MW:4541.07
EINECS:232-659-7
Product Categories:Peptide;Melanocortin receptor
storage temp.:−20°C
solubility H2O: 1 mg/mL, clear, colorless
Usage:Increased: seen in stress states, primary adrenal insufficiency, Cushing syndrome, Nelson syndrome, congenital adrenal hyperplasia, pituitary adrenocorticocytoma. Decrease: seen in hypopituitarism, adrenal cortical tumors, pituitary tumors, and anterior pituitary lesions.

Seractide is potent endogenous melanocortin receptor 2 (MC ) agonist (EC = 57 pM). Component of the hypothalamic-pituitary-adrenal (HPA) axis that stimulates glucocorticoid production and release from the adrenal cortex. Induces resistance, promotes a proinflammatory profile and stimulates UCP-1 in adipocytes in vitro



Fuction:

1.Endocrine Disorders: Nonsuppurative thyroiditis; Hypercalcemia associated with cancer.
2.Nervous System Diseases: Acute exacerbations of multiple sclerosis.
3.Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation)
4.Collagen Diseases: During an exacerbation or as maintenance therapy
5.Dermatologic Diseases: Pemphigus; bullous dermatitis herpetiformis
6.Allergic States: Control of severe or incapacitating allergic conditions


Cycle and dosage:

Adipotide is a new drug that is showing some promise in the area of obesity research. This drug was initially created as a cancer treatment designed to starve cancer cells of a blood supply so they would stop growing. The effects of Adipotide have shown that the drug actually starves fat cells of blood forcing them to die and be reabsorbed into the body. Initial tests were done on rats and then moved on to monkeys. The results from testing on rats showed a 30 percent decrease in body weight. After four weeks of daily injections of Adipotide followed by four weeks of non-treatment, 10 obese female rhesus monkeys lost an average of 11 percent of their body weight and 39 percent of fat deposits. Most of the loss was experienced during the non-treatment period.

After CTH was orally administered, it was destroyed in the stomach by pepsin and was only available for injection. Plasma t1/2 is 15 minutes. It is at normal plasma concentrations of 22 pg/ml at 8 am and 9.6 pg/ml at 10 pm. Its main role is to promote the secretion of glucocorticoids, but only when the cortical function is intact can play a therapeutic role. Typically, the cortex begins to secrete hydrocortisone 2 hours after administration.








 

Human Peptides ACTH (1-39) Seractide 10mg/Vial for Adrenal insufficiency

Product Name:Seractide
CAS:12279-41-3
MF:C207H308N56O58S1
MW:4541.07
EINECS:232-659-7
Product Categories:Peptide;Melanocortin receptor
storage temp.:−20°C
solubility H2O: 1 mg/mL, clear, colorless
Usage:Increased: seen in stress states, primary adrenal insufficiency, Cushing syndrome, Nelson syndrome, congenital adrenal hyperplasia, pituitary adrenocorticocytoma. Decrease: seen in hypopituitarism, adrenal cortical tumors, pituitary tumors, and anterior pituitary lesions.

Seractide is potent endogenous melanocortin receptor 2 (MC ) agonist (EC = 57 pM). Component of the hypothalamic-pituitary-adrenal (HPA) axis that stimulates glucocorticoid production and release from the adrenal cortex. Induces resistance, promotes a proinflammatory profile and stimulates UCP-1 in adipocytes in vitro



Fuction:

1.Endocrine Disorders: Nonsuppurative thyroiditis; Hypercalcemia associated with cancer.
2.Nervous System Diseases: Acute exacerbations of multiple sclerosis.
3.Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation)
4.Collagen Diseases: During an exacerbation or as maintenance therapy
5.Dermatologic Diseases: Pemphigus; bullous dermatitis herpetiformis
6.Allergic States: Control of severe or incapacitating allergic conditions


Cycle and dosage:

Adipotide is a new drug that is showing some promise in the area of obesity research. This drug was initially created as a cancer treatment designed to starve cancer cells of a blood supply so they would stop growing. The effects of Adipotide have shown that the drug actually starves fat cells of blood forcing them to die and be reabsorbed into the body. Initial tests were done on rats and then moved on to monkeys. The results from testing on rats showed a 30 percent decrease in body weight. After four weeks of daily injections of Adipotide followed by four weeks of non-treatment, 10 obese female rhesus monkeys lost an average of 11 percent of their body weight and 39 percent of fat deposits. Most of the loss was experienced during the non-treatment period.

After CTH was orally administered, it was destroyed in the stomach by pepsin and was only available for injection. Plasma t1/2 is 15 minutes. It is at normal plasma concentrations of 22 pg/ml at 8 am and 9.6 pg/ml at 10 pm. Its main role is to promote the secretion of glucocorticoids, but only when the cortical function is intact can play a therapeutic role. Typically, the cortex begins to secrete hydrocortisone 2 hours after administration.